A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
Clinical trial NCT01034163 · COMPLETED
Trial details
- NCT number
- NCT01034163
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2010-06-01
- Primary completion
- 2012-05-01
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.